TD Asset Management
URGN icon

TD Asset Management’s UroGen Pharma URGN Stock Holding History

TD Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80,188
Closed -$1.88M – 1301
2025
Q4 		$1.88M Buy
80,188
+36,188
+82% +$785K ﹤0.01% 997
2025
Q3 		$878K Sell
44,000
-9,400
-18% -$169K ﹤0.01% 1113
2025
Q2 		$732K Hold
53,400
– – ﹤0.01% 1098
2025
Q1 		$591K Hold
53,400
– – ﹤0.01% 1128
2024
Q4 		$569K Buy
+53,400
New +$639K ﹤0.01% 1173
2024
Q2 		– Sell
-32,800
Closed -$492K – 1426
2024
Q1 		$492K Buy
+32,800
New +$536K ﹤0.01% 1298

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

TD Asset Management's URGN Position: Q1 2026 in Review

TD Asset Management sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 80,188 shares — an estimated $1.88M sold.

TD Asset Management first reported a position in URGN in Q1 2024 and held it in 6 quarters. The position peaked at $1.88M in Q4 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • TD Asset Management reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • TD Asset Management sold 80,188 UroGen Pharma shares in Q1 2026, an estimated $1.88M.
  • TD Asset Management first reported a position in UroGen Pharma in Q1 2024 and held it in 6 quarters.
  • TD Asset Management's UroGen Pharma position peaked at $1.88M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.